What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

Critical Reviews in Oncology/Hematology

Volumn 95, Issue 3, 2015, Pages 306-317

  Bronte, Giuseppe ^a   Rolfo, Christian ^b   Passiglia, Francesco ^a   Rizzo, Sergio ^a   Gil Bazo, Ignacio ^c   Fiorentino, Eugenio ^a   Cajozzo, Massimo ^a   Van Meerbeeck, Jan P ^b   Lequaglie, Cosimo ^d   Santini, Daniele ^e   Pauwels, Patrick ^b   Russo, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Chemotherapy; Doublet; NSCLC; Performance status; Platinum; Single agent

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; VINDESINE; ANTINEOPLASTIC AGENT; PLATINUM;

ANEMIA; BLOOD TOXICITY; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; META ANALYSIS; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MORTALITY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PLATINUM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 84938214982     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.03.010     Document Type: Review

References (35)

1. Mok T.S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
2. Rosell R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
3. Sequist L.V., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3327-3334.
4. Solomon B.J., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014, 371:2167-2177.
5. Bronte G., et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev 2010, 36(Suppl. 3):S21-S29.
6. Peters S., et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(Suppl. 7). vii56-vii64.
7. Buccheri G., Ferrigno D., Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996, 32A:1135-1141.
8. Kelly K. Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status. Semin Oncol 2004, 31:3-7.
9. Oken M.M., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
10. Stanley K.E. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980, 65:25-32.
11. Lilenbaum R.C. Treatment of patients with advanced lung cancer and poor performance status. Clin Lung Cancer 2004, 6(Suppl. 2):S71-S74.
12. Boukovinas I., Kosmidis P. Treatment of non-small cell lung cancer patients with performance status2 (PS2). Lung Cancer 2009, 63:10-15.
13. Gridelli C., et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 2004, 15:419-426.
14. Group N.M.-A.C. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008, 26:4617-4625.
15. Russo A., et al. Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a literature-based meta-analysis. Cancer 2009, 115:1924-1931.
16. Ramalingam S.S., Khuri F.R. The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer. Oncologist 2009, 14:412-424.
17. Owonikoko T.K., Ramalingam S.S., Khuri F.R. Lung cancer in the elderly: what's age got to do with it?. Oncology (Williston Park) 2010, 24:1120. 1122, 1129.
18. Zukin M., et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and eastern cooperative oncology group performance status of 2. J Clin Oncol 2013, 31:2849-2853.
19. Morabito A., et al. Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study. Lung Cancer 2013, 81:77-83.
20. Moher D., Liberati A., Tetzlaff J., Altman D.G., Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535.
21. Reynolds C., et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009, 27:5808-5815.
22. Lilenbaum R.C., et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005, 23:190-196.
23. Le Chevalier T., et al. Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist 2001, 6(Suppl. 1):8-11.
24. Kosmidis P.A., et al. Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group. J Thorac Oncol 2007, 2:135-140.
25. Quoix E., et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011, 378:1079-1088.
26. Klastersky J., et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990, 8:1556-1562.
27. Jelić S., et al. Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study. Lung Cancer 2001, 34:1-13.
28. Rosell R., et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002, 13:1539-1549.
29. Schiller J.H., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
30. Zatloukal P., et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 2003, 41:321-331.
31. Fossella F., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003, 21:3016-3024.
32. Mazzanti P., et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2003, 41:81-89.
33. Paccagnella A., et al. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 2004, 43:83-91.
34. Ardizzoni A., et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007, 99:847-857.
35. de Castria T.B., da Silva E.M., Gois A.F., Riera R. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev 2013, 8:CD009256.